Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation

NCT06619587 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT06619587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06619587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 14, 2024
Completion date
May 31, 2028
Enrollment
410 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor